Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q2 2015 · 10-Q
Revenue$20.00K$20.00K−20.0% vs Q2 2014 Net Income$26.86M$26.86MN/M vs Q2 2014 EPS Diluted$5.47$5.47— vs Q2 2014 Gross Profit$20,000+150.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,293,000N/M Margins · derivedGross margin100.0%+68.0 pt vs Q2 2014
Operating margin-7155.0%−6739.0 pt vs Q2 2014
Net margin134300.0%+135348.0 pt vs Q2 2014
ended Jun 30, 2015 · filed Aug 14, 2015 · 45 d after period end